BPG is committed to discovery and dissemination of knowledge
Featured Articles
4/29/2022 7:25:52 AM | Browse: 174 | Download: 211
Publication Name World Journal of Gastroenterology
Manuscript ID 72512
Country/Territory United States
Received
2021-10-19 02:29
Peer-Review Started
2021-10-19 02:31
To Make the First Decision
Return for Revision
2021-12-03 20:24
Revised
2022-01-07 16:01
Second Decision
2022-03-22 06:37
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-03-27 05:33
Articles in Press
2022-03-27 05:33
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2022-04-01 14:15
Publish the Manuscript Online
2022-04-29 06:42
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Radiology, Nuclear Medicine & Medical Imaging
Manuscript Type Minireviews
Article Title Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
Manuscript Source Invited Manuscript
All Author List Neil Grey, Michael Silosky, Christopher H Lieu and Bennett B Chin
Funding Agency and Grant Number
Corresponding Author Bennett B Chin, MD, Professor, Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus, 12401 East 17th Avenue, Mail Stop L954A, Aurora, CO 80045, United States. bennett.chin@cuanschutz.edu
Key Words DOTATATE; Theranostics; Gastroenteropancreatic neuroendocrine tumors; 68Ga DOTATATE; 177Lu DOTATATE; Review
Core Tip 68Ga and 64Cu DOTATATE positron emission tomography imaging is the most sensitive and accurate method to identify well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The paired therapeutic radiotracer, 177Lu DOTATATE, delivers targeted radiation which can prolong progression free survival. This is now established as the therapeutic best standard of care for patients with progressive, metastatic, or unresectable well-differentiated somatostatin receptors positive GEP-NETs. Ongoing investigations continue to expand the potential indications for DOTATATE theranostics. Additional novel ligands are also currently being developed for targeted imaging and therapy of GEP-NETs.
Publish Date 2022-04-29 06:42
Citation Grey N, Silosky M, Lieu CH, Chin BB. Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. World J Gastroenterol 2022; 28(17): 1768-1780
URL https://www.wjgnet.com/1007-9327/full/v28/i17/1768.htm
DOI https://dx.doi.org/10.3748/wjg.v28.i17.1768
Full Article (PDF) WJG-28-1768.pdf
Full Article (Word) WJG-28-1768.docx
Manuscript File 72512_Auto_Edited.docx
Answering Reviewers 72512-Answering reviewers.pdf
Audio Core Tip 72512-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 72512-Conflict-of-interest statement.pdf
Copyright License Agreement 72512-Copyright license agreement.pdf
Peer-review Report 72512-Peer-review(s).pdf
Scientific Misconduct Check 72512-Bing-Fan JR-2.png
Scientific Editor Work List 72512-Scientific editor work list.pdf